Moreover, they found that LIF attenuated liver steatosis via binding to LIFR and activating the STAT3 pathway, which provided a rationale for LIF–LIFR to be a potential therapeutic target for NAFLD treatment. Here, STAT3 is linked to metabolic dysfunction-associated steatotic liver disease.